This paper is only available as a PDF. To read, Please Download here.
Abstract
Despite recent advances in breast cancer therapy, women with similar types of breast
cancers may respond very differently to standard treatments. The emerging field of
clinical proteomics has the potential to revolutionize breast cancer therapy. The
ultimate goal of clinical proteomics is to characterize information flow through protein
cascades for individual patients. After the protein networks have been elucidated,
drug therapies may be specially designed for each patient. The following review describes
the proteomic technologies of laser-capture microdissection (LCM) and reverse-phase
protein arrays (RPPAs). These technologies allow scientists to analyze relative abundances
of key cellular signaling proteins from pure cell populations. Cell survival and apoptotic
protein pathways are currently being monitored with LCM and RPPAs at the National
Institutes of Health, in phase II clinical trials of metastatic breast and ovarian
cancers. Ultimately, proteomics will become an integral component of tracking and
managing individualized breast cancer therapy.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer Medicine. 4th ed. Williams & Wilkins, Baltimore1997
- Clinical proteomics: translating benchside promise into bedside reality.Nat Rev Drug Discov. 2002; 1: 683-695
- Proteomics of breast cancer for marker discovery and signal pathway profiling.Proteomics. 2001; 1: 1216-1232
- Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.Oncogene. 2001; 20: 1981-1989
- Histological and biological evolution of human premalignant breast disease.Endocr Relat Cancer. 2001; 8: 47-61
- Laser capture microdissection: beyond functional genomics to proteomics.Mol Diagn. 2000; 5: 301-307
- The hallmarks of cancer.Cell. 2000; 100: 57-70
- The microenvironment of the tumour-host interface.Nature. 2001; 411: 375-379
- Tumorigenic conversion of immortal human keratinocytes through stromal cell activation.Proc Natl Acad Sci U S A. 1998; 95: 1050-1055
- Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.Cancer Res. 1999; 59: 5002-5011
- Clinical proteomics: personalized molecular medicine.JAMA. 2001; 286: 2211-2214
- Use of proteomic analysis to monitor responses to biological therapies.Expert Opin Biol Ther. 2004; 4: 83-93
- Protein microarrays: meeting analytical challenges for clinical applications.Cancer Cell. 2003; 3: 317-325
- Apoptosis-targeted therapies for cancer.Cancer Cell. 2003; : 317-322
- Dysregulation of apoptosis in cancer.J Clin Oncol. 1999; 17: 2941-2953
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib.N Engl J Med. 2004; 350: 2129-2139
- Integrated genomic and proteomic analyses of a systematically perturbed metabolic network.Science. 2001; 292: 929-934
- A comparison of selected mRNA and protein abundances in human liver.Electrophoresis. 1997; 18: 533-537
- Proteomics of human breast ductal carcinoma in situ.Cancer Res. 2002; 62: 6740-6749
- Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines.Electrophoresis. 2000; 21: 2235-2242
- New approaches to proteomic analysis of breast cancer.Proteomics. 2001; 1: 1205-1215
- Laser capture microdissection: molecular analysis of tissue.Science. 1997; 278: 1481-1483
- Tissue microdissection and its applications in pathology.Curr Diagn Pathol. 2002; 8: 183-192
- Protein microarrays: molecular profiling technologies for clinical specimens.Proteomics. 2003; 3: 2091-2100
- Utility of reverse phase protein arrays: Applications to signaling pathways and human body arrays.Briefings Functional Genomics Proteomics. 2002; 1: 305-315
- Laser capture microdissection.Science. 1996; 274: 998-1001
- High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer.Br J Cancer. 2001; 84: 493-498
- Gene expression profiles of human breast cancer progression.Proc Natl Acad Sci U S A. 2003; 100: 5974-5979
- Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.Cancer Res. 2000; 60: 3884-3892
- In vivo gene expression profile analysis of human breast cancer progression.Cancer Res. 1999; 59: 5656-5661
- Microdissection is essential for gene expression profiling of clinically resected cancer tissues.Am J Clin Pathol. 2002; 117: 109-116
- Laser capture microdissection and advanced molecular analysis of human breast cancer.J Mammary Gland Biol Neoplasia. 2003; 8: 335-345
- Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions.Hum Mol Genet. 2001; 10: 1907-1913
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.Cancer Cell. 2004; 5: 607-616
- Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications.Proteomics. 2003; 3: 413-421
- Evaluation of non-formalin tissue fixation for molecular profiling studies.Am J Pathol. 2002; 160: 449-457
- Molecular profiling of clinical tissue specimens: feasibility and applications.Am J Pathol. 2000; 156: 1109-1115
- Proteomic profiling of the cancer microenvironment by antibody arrays.Proteomics. 2001; 1: 1271-1278
- UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions.Nucleic Acids Res. 2000; 28: e3
- Protein microarrays for gene expression and antibody screening.Anal Biochem. 1999; 270: 103-111
- Protein microchips: use for immunoassay and enzymatic reactions.Anal Biochem. 2000; 278: 123-131
- Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions.Genome Biol. 2001; (research0004.1-0004.13.): 2
- Tissue microarrays for high-throughput molecular profiling of tumor specimens.Nat Med. 1998; 4: 844-847
- Protein microarray technology.Drug Discov Today. 2002; 7: 815-822
- Recent developments in protein microarray technology.Angew Chem Int Ed Engl. 2003; 42: 494-500
- Antibody arrays: an embryonic but rapidly growing technology.Drug Discov Today. 2002; 7: S143-S149
- Printing proteins as microarray for highthroughput function determination.Science. 2000; 5485: 1760-1763
- Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer.Dis Markers. 2001; 17: 301-307
- Protein chip technology.Curr Opin Chem Biol. 2003; 7: 55-63
- Protein arrays for assessment of target selectivity.Drug Discov World. 2002; 1: 17-27
- Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays.Proteomics. 2003; 3: 2085-2090
- Clinical proteomics: technology for monitoring drug treatment effects on in vivo signal pathways in cancer cells obtained by biopsy.Proc Am Assoc Cancer Res. 2003; 94 (Abstract #2963).: 677
- Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.J Clin Oncol. 2005; (In press).
- Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.Semin Oncol. 2000; 27: 13-19
Article info
Publication history
Accepted:
August 6,
2004
Received in revised form:
August 5,
2004
Received:
June 16,
2004
Identification
Copyright
© 2004 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
